Sinocelltech Group Receives NMPA Approval for SCTT11 Clinical Study in Thyroid Eye Disease
China-based Sinocelltech Group Ltd (SHA: 688520) has announced receiving approval from the National Medical Products...
SHA: 688520
Sinocelltech’s Finotonlimab Gets NMPA Approval for Liver Cancer Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received another indication approval from...
NMPA Approves Sinocelltech’s Finotonlimab for Head and Neck Cancer
The National Medical Products Administration (NMPA) of China has approved Sinocelltech Group Ltd’s (SHA: 688520)...
Sinocelltech’s Herpes Zoster Vaccine SCTV04C Clears NMPA for Clinical Trial
Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has received approval from...
Sinocelltech’s Anti-Angiogenic Biologic SCT520FF Gets NMPA Green Light for Neovascular AMD Clinical Study
SHANGHAI—Sinocelltech Group Ltd (SHA: 688520), a Chinese biopharmaceutical company, has announced that it has received...
Sinocelltech Gains NMPA Approval for Clinical Study of SCTB35 in B-Cell Non-Hodgkin’s Lymphoma
Sinocelltech Group Ltd (SHA: 688520), based in China, has announced that it has received clearance...
Sinocelltech Granted NMPA Approval for Phase I Clinical Trial in Hematological Malignancies
Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has announced that it...
Chinese Firms Secure EUAs for Omicron XBB Vaccines Amid Dominant Variant Surge
A wave of Chinese pharmaceutical companies has announced the receipt of Emergency Use Authorizations (EUAs)...
Sinocelltech’s PD-1 Inhibitor SCT-I10A for HNSCC Accepted for NMPA Review
Sinocelltech Group Ltd (SHA: 688520), a Chinese biopharmaceutical company, has announced that its market approval...
Sinocelltech Group Receives NMPA Approval for Bevacizumab Biosimilar for Multiple Cancers
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received marketing approval from...
Sinocelltech Group Receives NMPA Approval for COVID-19 Vaccine Bridging Phase II Study
China-based Sinocelltech Group Ltd (SHA: 688520) has announced receiving approval from the National Medical Products...
Sinocelltech Group Launches Biosimilar Version of AbbVie’s Humira in China
China-based Sinocelltech Group Ltd (SHA: 688520) has officially commercialized its biosimilar version of AbbVie’s (NYSE:...
Sinocelltech Group Receives NMPA Approval for Biosimilar Version of Humira
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received market approval from...
Sinocelltech’s SCTV01C Vaccine Included in China’s Emergency Use Program
China-based Sinocelltech Group Ltd (SHA: 688520) announced the inclusion of its recombinant novel coronavirus alpha+beta...
Sinocelltech’s SCTV01E Vaccine Receives NMPA Approval for Phase II Study
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received approval from the...
Sinocelltech’s COVID-19 Vaccines SCTV01C and SCTV01E Show Promising Phase III Results
China-based Sinocelltech Group Ltd (SHA: 688520) has announced the preliminary interim analysis results of a...
Sinocelltech’s Ripertamab Officially Launched in China for DLBCL Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) announced the first deliveries and prescriptions of its ripertamab...
Sinocelltech’s Ripertamab Wins NMPA Approval for DLBCL Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) has received New Drug Application (NDA) approval from the...